Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters
AA Rosenkranz, TA Slastnikova, GP Georgiev… - Nuclear Medicine and …, 2020 - Elsevier
The presence of Auger electrons (AE) among the decay products of a number of
radionuclides makes these radionuclides an attractive means for treating cancer because …
radionuclides makes these radionuclides an attractive means for treating cancer because …
A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
JYC Wong, S Shibata, LE Williams, CS Kwok, A Liu… - Clinical Cancer …, 2003 - AACR
Purpose: Targeted systemic radiation therapy using radiolabeled antibodies results in tumor
doses sufficient to produce significant objective responses in the radiosensitive …
doses sufficient to produce significant objective responses in the radiosensitive …
First-In-Human Pilot PET Immunoimaging Study of 64Cu-Anti-Carcinoembryonic Antigen Monoclonal Antibody (hT84.66-M5A) in Patients with Carcinoembryonic …
JYC Wong, DM Yamauchi, V Adhikarla… - Cancer Biotherapy & …, 2023 - liebertpub.com
Background: PET imaging using radiolabeled immunoconstructs shows promise in cancer
detection and in assessing tumor response to therapies. The authors report the first-in …
detection and in assessing tumor response to therapies. The authors report the first-in …
PET imaging of 86Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between 86Y and 111In radiolabels
A Lövqvist, JL Humm, A Sheikh, RD Finn… - Journal of Nuclear …, 2001 - Soc Nuclear Med
Absorbed doses in 90Y radioimmunotherapy are usually estimated by extrapolating from
111In imaging data. PET using 86Y (β+ 33%; half-life, 14.7 h) as a surrogate radiolabel …
111In imaging data. PET using 86Y (β+ 33%; half-life, 14.7 h) as a surrogate radiolabel …
[HTML][HTML] 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
EMJ van Brummelen, MC Huisman, TK Nayak… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against
carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor (IL …
carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor (IL …
The crystal structure of an anti-CEA scFv diabody assembled from T84. 66 scFvs in VL-to-VH orientation: implications for diabody flexibility
JA Carmichael, BE Power, TPJ Garrett… - Journal of molecular …, 2003 - Elsevier
Diabodies (scFv dimers) are small, bivalent antibody mimetics of approximately 55kDa in
size that possess rapid in vivo targeting pharmacokinetics compared to the intact parent …
size that possess rapid in vivo targeting pharmacokinetics compared to the intact parent …
Improved antibody-guided surgery with a near-infrared dye on a pegylated linker for CEA-positive tumors
PJ Yazaki, TM Lwin, M Minnix, L Li… - Journal of …, 2019 - spiedigitallibrary.org
Real-time intraoperative image-guided cancer surgery promises to improve oncologic
outcomes. Tumor-specific antibodies conjugated with near-infrared (NIR) fluorophores have …
outcomes. Tumor-specific antibodies conjugated with near-infrared (NIR) fluorophores have …
Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal …
JYC Wong, DZ Chu, LE Williams, DM Yamauchi… - Clinical cancer …, 2004 - AACR
Abstract Purpose: The chimeric T84. 66 (cT84. 66) minibody is a novel engineered antibody
construct (VL-linker-VH-CH3; 80 kDa) that demonstrates bivalent and high affinity (4× 1010 …
construct (VL-linker-VH-CH3; 80 kDa) that demonstrates bivalent and high affinity (4× 1010 …
A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing …
JYC Wong, DZ Chu, DM Yamauchi, LE Williams… - Clinical cancer …, 2000 - AACR
Abstract Chimeric T84. 66 (cT84. 66) is a genetically engineered human/murine chimeric
IgG1 with high affinity and specificity to carcinoembryonic antigen (CEA). The purpose of this …
IgG1 with high affinity and specificity to carcinoembryonic antigen (CEA). The purpose of this …
[HTML][HTML] In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated …
Carcinoembryonic antigen (CEA) is an antigen highly expressed in colorectal cancers, and
widely used as a tumor marker. 131I and 90Y-radiolabeled anti-CEA monoclonal antibodies …
widely used as a tumor marker. 131I and 90Y-radiolabeled anti-CEA monoclonal antibodies …